Zentalis Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis
Zentalis Pharmaceuticals, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage WEE1 inhibitor pure-play with cash runway to late 2027 and potential accelerated approval pathway in platinum-resistant ovarian cancer, but faces binary clinical and regulatory risk. With a market cap of $152M and trailing 12-month revenue of $26.9M, Zentalis faces typical clinical-stage biotech risks. The company has strong cash.
What is Zentalis Pharmaceuticals, Inc.'s industry? Zentalis Pharmaceuticals, Inc. (zentalis.com) operates in Biotechnology / Oncology. AskCyborg classifies Zentalis Pharmaceuticals, Inc. under Biotechnology / Oncology in its company registry.
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer treatment, with its lead program azenosertib in Phase 3 clinical tria...
Cyborg Score thesis
Early-stage WEE1 inhibitor pure-play with cash runway to late 2027 and potential accelerated approval pathway in...
Read the full analyst-debate transcript →Get the Latest Zentalis Pharmaceuticals, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeZentalis Pharmaceuticals, Inc. Overview
Pro stress-test →Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer treatment, with its lead program azenosertib in Phase 3 clinical trials for ovarian cancer and other tumor types. The company targets fundamental cancer biology pathways through its integrated discovery engine approach.
Strategic Profile
Pro stress-test →The company is developing azenosertib as a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer. The Phase 2 DENALI trial remains on track with topline data expected by year-end 2026 with potential to support accelerated approval.
Competitive Landscape
Pro stress-test →Competitors include ORIC Pharmaceuticals, Prelude Therapeutics, Hookipa Pharma, Ayala Pharmaceuticals, and Enliven Therapeutics. Zentalis differentiates through its WEE1 inhibitor approach and biomarker-driven patient selection strategy targeting Cyclin E1-positive populations in platinum-resistant ovarian cancer.
Industry Context
Zentalis Pharmaceuticals, Inc. operates in Biotechnology / Oncology.
Key facts
Founded: 2014 · Headquarters: San Diego, CA, United States · Employees: 166 · Revenue: $26.9M · Market cap: $152M